2-(Methylamino)ethanol
Based on 1 Customer Validation
2-(Methylamino) ethanol (N-Methylethanolamine) is an orally active Phospholipase D inhibitor and analog of Ethanolamine (HY-Y0524). 2-(Methylamino) ethanol reduces the mRNA levels of ACE, ppET-1 and ECE-1, and inhibits MMP-2 activity. 2-(Methylamino) ethanol inhibits Collagen synthesis. 2-(Methylamino) ethanol attenuates ventricular hypertrophy, prevents increased myocardial stiffness and hemodynamic deterioration. 2-(Methylamino) ethanol can capture industrial acid gases and react with carbon dioxide to form carbamates and bicarbonates. 2-(Methylamino) ethanol can be used in studies related to hypertensive heart failure (diastolic heart failure).
For research use only. We do not sell to patients.
- Purity: 99.86%
- CAS No.: 109-83-1
- Formula: C3H9NO
- Molecular Weight:75.11
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All Phospholipase Isoforms
More
Biological Activity
|
MMP-2 |
Phospholipase D |
2-(Methylamino) ethanol (1-3 mM; 18 h) reduces PLD activity in Detroit-551 skin fibroblasts in a dose-dependent manner, with a significant reduction observed at 3 mM[1].
2-(Methylamino) ethanol (1-3 mM; 48 h) inhibits collagen synthesis in Detroit-551 skin fibroblasts in a dose-dependent manner, with significant inhibitory effects observed at concentrations of 1 mM and 3 mM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Detroit-551 (ATCC CCL 110) human skin fibroblasts
-
Concentration:1 mM, 3 mM
-
Incubation Time:48 h
-
Result:Increased MMP-1 production to ~750 ng/mL at 1 mM, a non-significant change compared to the control.
Increased MMP-1 production to ~1050 ng/mL at 3 mM, a statistically significant increase compared to both the control and the 1 mM dose (p < 0.05 vs. 0 mM; p < 0.05 vs. 1 mM).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Dahl salt-sensitive (male, 8 weeks old at treatment start, fed 8% NaCl from 7 weeks to induce hypertensive heart failure); Wistar (male, toxicity cohort)[1]
-
Dosage:200 mg/kg/day (hypertensive heart failure model); 400 mg/kg/day (toxicity cohort)
-
Administration:p.o.; daily; 11 weeks (Dahl salt-sensitive rats); p.o.; daily; 2 weeks (Wistar rats)
-
Result:Normalized left ventricular end-diastolic pressure to control levels.
Normalized lung weight/tibial length to control levels.
Decreased PLD activity to 46% of control levels.
Reduced LV hydroxyproline concentration from 4.2 μmol/g to 2.7 μmol/g.
Lowered LV area of fibrosis from 10.5% to 4.5%.
Reduced LV mass/tibial length from 31.1 mg/mm to 26.0 mg/mm.
Reduced LV myocyte diameter from 23.8 μm to 22.6 μm.
Decreased mRNA levels of collagen type I, collagen type III, ACE, ppET-1, and ECE-1.
Reduced 72 kDa gelatinase (MMP-2) activity.
Did not significantly reduce systolic blood pressure.
Resulted in a mean body weight of 339 g in Wistar rats (vs. 366 g in controls).
Reduced alanine aminotransferase to 27 mU/mL in Wistar rats (vs. 53 mU/mL in controls).
Reduced alkaline phosphatase to 380 mU/mL in Wistar rats (vs. 533 mU/mL in controls).
Increased total protein to 7.38 g/dL in Wistar rats (vs. 6.67 g/dL in controls).
Increased albumin to 3.47 g/dL in Wistar rats (vs. 2.98 g/dL in controls).
Chemical Information
-
CAS No. 109-83-1
-
Appearance Liquid (Density: 0.935 g/cm3)
-
Molecular Weight 75.11
-
Formula C3H9NO
-
Color Colorless to light yellow
-
SMILES
CNCCO
-
Synonyms
N-Methylethanolamine
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 200 mg/mL (2662.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (782 KB)
- English - EN (782 KB)
- Français - FR (782 KB)
- Deutsch - DE (782 KB)
- Norwegian - NO (782 KB)
- Español - ES (782 KB)
- Swedish - SV (782 KB)
- Italian - IT (782 KB)
- Korean - KR (782 KB)
- Portuguese - PT (782 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 13.3138 mL | 66.5690 mL | 133.1381 mL | 332.8452 mL |
| 5 mM | 2.6628 mL | 13.3138 mL | 26.6276 mL | 66.5690 mL | |
| 10 mM | 1.3314 mL | 6.6569 mL | 13.3138 mL | 33.2845 mL | |
| 15 mM | 0.8876 mL | 4.4379 mL | 8.8759 mL | 22.1897 mL | |
| 20 mM | 0.6657 mL | 3.3285 mL | 6.6569 mL | 16.6423 mL | |
| 25 mM | 0.5326 mL | 2.6628 mL | 5.3255 mL | 13.3138 mL | |
| 30 mM | 0.4438 mL | 2.2190 mL | 4.4379 mL | 11.0948 mL | |
| 40 mM | 0.3328 mL | 1.6642 mL | 3.3285 mL | 8.3211 mL | |
| 50 mM | 0.2663 mL | 1.3314 mL | 2.6628 mL | 6.6569 mL | |
| 60 mM | 0.2219 mL | 1.1095 mL | 2.2190 mL | 5.5474 mL | |
| 80 mM | 0.1664 mL | 0.8321 mL | 1.6642 mL | 4.1606 mL | |
| 100 mM | 0.1331 mL | 0.6657 mL | 1.3314 mL | 3.3285 mL |
2-(Methylamino)ethanol Related Classifications
HY-Y1783 Related Classifications
Powered by Bioz
- 2-(Methylamino)ethanol
- 109-83-1
- N-Methylethanolamine
- Phospholipase
- Drug Derivative
- Angiotensin-converting Enzyme (ACE)
- Endothelin Receptor
- MMP
- Collagen
- Biochemical Assay Reagents
- hypertensive heart failure
- Wistar rats
- collagen synthesis
- phospholipase D
- ventricular hypertrophy
- Detroit-551 human skin fibroblasts
- MMP-2
- cardiac fibrosis
- collagenase
- myocardial stiffening
- Inhibitor
- inhibitor
- inhibit